Tetravalent antibody-scTRAIL fusion proteins with improved properties.
about
Novel drugs that target the metabolic reprogramming in renal cell cancerLactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic RelevanceOnto better TRAILs for cancer treatmentPrinciples of antibody-mediated TNF receptor activationMetabolic plasticity underpins innate and acquired resistance to LDHA inhibitionAdipose tissue dysfunction and its effects on tumor metabolismHIF1/2α mediates hypoxia-induced LDHA expression in human pancreatic cancer cellsIsoform switch of pyruvate kinase M1 indeed occurs but not to pyruvate kinase M2 in human tumorigenesis.Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer.The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancerAn optimized antibody-single-chain TRAIL fusion protein for cancer therapy.Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer.Essential protective role of tumor necrosis factor receptor 2 in neurodegenerationLDHB may be a significant predictor of poor prognosis in osteosarcoma.miR-200b is a key regulator of tumor progression and metabolism targeting lactate dehydrogenase A in human malignant glioma.Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinomaPredicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer.Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.MiR-34b-3 and miR-449a inhibit malignant progression of nasopharyngeal carcinoma by targeting lactate dehydrogenase A.A four-gene signature predicts survival in clear-cell renal-cell carcinomaStable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival.Ubiquitin ligase SMURF1 functions as a prognostic marker and promotes growth and metastasis of clear cell renal cell carcinoma.Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study.Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2.2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis.Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma.Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.SERPINH1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker.Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses.Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer.IgG-single-chain TRAIL fusion proteins for tumour therapy.Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways.Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma.
P2860
Q26740187-F952F534-1A0B-4DF6-9431-B19DB680F893Q26766711-B80D0A59-7B32-4CCB-9F8F-5E79F0FC81D0Q26768160-F9D6D534-DC63-47C7-BFD2-C518F26F4A78Q26796270-4ED61F85-38BD-4869-9F7D-7DD935B85E14Q27723745-383C887D-54ED-416F-8F23-AB33C2B176B4Q28080748-79D1B931-FE1B-418A-AACC-D99B1B544F0CQ33648672-CEE53BE2-4E23-45E3-8E78-B07E79E1F7CAQ35571437-AD09AB79-E46B-458F-9816-616D21670416Q35590091-E4484D85-588A-40E4-ABC9-A7B10D88D565Q36197277-018EBCB2-3FBF-4FDF-89A6-1F37B1415946Q36260554-863691A2-C5EB-4AFC-B6BD-6E651746C99AQ36605807-CA1ADE09-ADB5-435D-9E2B-8E14ED6D5874Q37141627-A51D5B26-C336-4EF6-8C01-8CE31D159641Q37290538-CE0E7EB4-C221-4EFF-99DA-C4CBBA684731Q37379859-E4EBE01F-0691-4829-812E-A6C70C1C6C35Q37448160-022029EB-5718-4F48-9E42-953AFC96C01FQ37565493-87F28427-391A-4D78-B690-F936433CD681Q37584289-400B88F2-D475-424C-B0F4-FF1F761EA4E1Q37641600-7FFAAC44-C5AB-4C43-AFFD-EEEEB6A39279Q37683757-341612FD-7458-423C-8A4E-24C4DDCE959AQ37687556-EB796934-EB3C-498F-AE79-70A362971AFAQ37688151-20BF6C53-882F-4F65-AFE7-4382EB43D900Q37696203-7F2705AC-9253-4E17-8861-762BCBE63897Q37718064-F7D40442-E0CD-4F82-AEC3-5A3B260E5389Q37734791-ED9C5416-2D7F-4C06-A94E-821B4618041FQ38648029-C67D9B5C-5DCC-4A49-BFEF-5D311B4E985BQ38659118-33843D99-0DCE-4541-88DC-EC9FE702A0B1Q38848483-71ABB1C0-242B-40D1-B0E6-1A4F21D3E290Q39097822-86970E4F-95CC-4EB5-B36F-A99D3E65BB90Q40114063-A8F51089-8F66-46DC-BE47-43DA67540A0EQ40294268-9B1495ED-9A1B-4610-BAB8-108E5177F886Q41686962-F21DAF3C-63AC-441F-B3A7-2DA95617FE63Q48119782-895B444C-9CF5-42B8-B58F-E1F2DBD590F8Q52599425-693F3C91-281F-4929-9AAB-513F4F62D6E3Q52649685-049CDA4E-8401-43E8-AD69-D5FD8FEF7E4AQ54998541-4125A0BD-EF54-4E48-9CB0-D564C02A94AEQ55012569-62630079-5CC6-4B83-BCEA-385710DD7C69Q55452513-B63D17C0-3C6A-401B-95DF-47F483D3E847Q55456133-8B872AF6-9B99-4CD5-8510-172920D93224
P2860
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
description
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
@ast
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
@en
type
label
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
@ast
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
@en
prefLabel
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
@ast
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
@en
P2093
P2860
P356
P1476
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
@en
P2093
Aline Plappert
Klaus Pfizenmaier
Martin Siegemund
Oliver Seifert
Roland E Kontermann
Sina Fellermeier
P2860
P304
P356
10.1186/1476-4598-13-101
P577
2013-10-03T00:00:00Z